Gamma delta T cell receptor immunotherapies - Gadega/Immunocore
Alternative Names: Gamma Delta TCR ImmTAC; γδ TCR ImmTacLatest Information Update: 09 Oct 2023
At a glance
- Originator Gadeta; Immunocore
- Class Gene therapies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Colorectal cancer; Solid tumours
Most Recent Events
- 02 Oct 2023 Gadeta has been acquired by Clade Therapeutics
- 02 Dec 2022 Gadeta and Immunocore agree to co-develop Gamme delta T cell receptor immunotherapies in United Kingdom and Netherlands in Solid tumours
- 02 Dec 2022 Early research in Colorectal cancer in Netherlands, United Kingdom (unspecified route)